Evaluation of efficacy due to response by FDG-PET in breast cancers treated with neoadjuvant chemotherapy

Evaluation of efficacy due to response by FDG-PET in breast cancers treated with neoadjuvant chemotherapy - PET NAC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030408

Enrollment

100

Registered

2017-12-15

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

FDG-PET examination between 2 to 6 weeks after start of neoadjuvant chemotherapy.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Primary breast cancer patients treated with neoaduvant chemotherapy.

Exclusion criteria

Exclusion criteria: Patients with Li-Fraumeni syndrome.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Contacts

Public ContactYasuo Miyoshi

Hyogo College of medicine Division of Breast and Endocrine, Department of Surgery

ymiyoshi@hyo-med.ac.jp0798456374

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026